How can we improve life expectancy and quality of life in long-term survivors after allogeneic stem cell transplantation?

Seminars in Hematology

Volumn 49, Issue 1, 2012, Pages 1-3

  Savani, Bipin N ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CANCER SURVIVOR; CHRONIC GRAFT VERSUS HOST DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; EDITORIAL; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; MORBIDITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RISK FACTOR;

CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIFE EXPECTANCY; LYMPHOMA, FOLLICULAR; QUALITY OF LIFE; SURVIVORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855400631     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.10.014     Document Type: Editorial

References (23)

1. Socie G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999, 341:14-21.
2. Socie G., Salooja N., Cohen A., et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003, 101:3373-3385.
3. Savani B.N., Griffith M.L., Jagasia S., Lee S.J. How I treat late effects in adults after allogeneic stem cell transplantation. Blood 2011, 117:3002-3009.
4. Lee S.J. Late critical problems in transplantation: an historical perspective. Hematology. Am Soc Hematol Educ Program 2008, 124.
5. Flowers M.E.D., Deeg H.J. Delayed nonmalignant complications after hematopoietic cell transplantation. Thomas' hematopoietic cell transplantation 2009, 1620-1637. Wiley-Blackwell, West Sussex, UK. F.R. Appelbaum, S.J. Forman, R.S. Negrin, K.G. Blume (Eds.).
6. Socie G., Curtis R.E., Deeg H.J., et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000, 18:348-357.
7. Rizzo J.D., Wingard J.R., Tichelli A., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006, 12:138-151.
8. Thomas E.D. A history of bone marrow transplantation. Thomas' hematopoietic cell transplantation 2009, 3-7. Wiley-Blackwell, West Sussex, UK. F.R. Appelbaum, S.J. Forman, R.S. Negrin, K.G. Blume (Eds.).
9. Horowitz M.M. Uses and growth of hematopoietic cell transplantation. Thomas' hematopoietic cell transplantation 2009, 15-21. Wiley-Blackwell, West Sussex, UK. F.R. Appelbaum, S.J. Forman, R.S. Negrin, K.G. Blume (Eds.).
10. Pasquini M.C., Wang Z., Aljurf M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2010 http://www.cibmtr.org.
11. Gratwohl A., Baldomero H., Aljurf M., et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010, 303:1617-1624.
12. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
13. Martin P.J., Counts G.W., Appelbaum F.R., et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010, 28:1011-1016.
14. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007, 110:3784-3792.
15. Tichelli A., Bhatia S., Socie G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol 2008, 142:11-26.
16. Williams K.M., Chien J.W., Gladwin M.T., Pavletic S.Z. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009, 302:306-314.
17. Majhail N.S., Brazauskas R., Rizzo J.D., et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011, 117:316-322.
18. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant 2006, 12:375-396.
19. Savani B.N., Montero A., Srinivasan R., et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:1261-1269.
20. Curtis R.E., Metayer C., Rizzo J.D., et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005, 105:3802-3811.
21. Savani B.N., Goodman S., Barrett A.J. Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation?. Clin Cancer Res 2009, 15:2219-2221.
22. Savani B.N., Donohue T., Kozanas E., et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:517-520.
23. Rizzo J.D., Curtis R.E., Socie G., et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1175-1183.